AZD6738 for Patients With Progressive MDS or CMML

Summary

This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .

Timeline

Start

2019-08-05

Primary completion

2025-04-09

Completion

2026-05-31

Publications

• Brunner AM, Liu Y, Garcia JS, Mendez LM, Gutierrez C, Nonavinkere Srivatsan S, Shao J, Aubrey BJ, Amrein PC, Narayan R, Vedula RS, Friedman E, Neuberg DS, Andrade Campos M, Smith SA, Stone RM, Fathi AT, Walter MJ, Graubert TA, Jacoby MA. A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML. Blood Adv. 2026 Jun 30:bloodadvances.2026019848. doi: 10.1182/bloodadvances.2026019848. Online ahead of print.

Drugs

Indications